Professor Esam Z. Dajani, Ph.D., FACG
has over 30 years of experience in Pharmaceutical Research & Development
with expertise in Clinical Pharmacology, Toxicology, Drug Development, Regulatory Affairs, Pharmaceutical Patents and Contract Research Organizations (CROs)
. He has directed worldwide clinical research at major pharmaceutical companies and led the research teams that discovered & developed misoprostol (Cytotec), a worldwide anti-ulcer drug. He has 260 publications, pharmaceutical patents and presentations. He is a licensed Pharmacist.
Professor Dajani is currently the President of IDDC Corporation, a CRO. He holds Adjunct Professor of Medicine appointment at Loyola-Chicago. He is able to evaluate the causal relationships between exposure to drugs or chemicals and the subsequent pharmacological and toxicological actions induced by such exposure. He has the expertise to simplify complex scientific facts to help the jury and the court understand the medical facts of the case. Serving both Plaintiff and Defense attorneys. He has experience in malpractice, criminal cases, pharmaceutical patent litigations, product liability, forensic aspects of alcohol, drug intoxications and administrative cases. Professor Dajani reviews affidavits, depositions, courtroom testimony, medical records, pharmaceutical records and is available for depositions and trial testimony.
Areas of Expertise
View Consulting Profile
- Drug Injury Causation
- Drug Patent Litigation
- Pharmacy Malpractice
- Drug-Related Medical Malpractice
- Medication Error Event Reconstruction
- Drug Product Liability - Warnings, Design, Formulation
- Adverse Effects of Health, Beauty Products, Alcohol and Industrial Chemicals
It is well established that the use of traditional nonsteroidal anti-inflammatory drugs (NSAIDs) increases the vulnerability of the gastrointestinal (GI) mucosa for the development of peptic lesions and serious ulcer complications. In addition, selective and traditional NSAIDs have also been associated with increased frequency of cardiovascular toxicity, especially in susceptible patients.
During the last twenty-five years, a remarkable revolution in the pathophysiology and treatment of gastric (GU) and duodenal (DU) ulcers has occurred. Effective therapies were developed not only to heal ulcers but also to cure most patients.
Esam Z. Dajani, N.M. Agrawal
A chapter in the book: NSAIDs - Mechanisms and Clinical Use. Eds. Lewis AJ, Furst D, Marcel Dekker, New York, PP 159-170, 1994.
Esam Z. Dajani, H. Gallo-Torres
Chapter in the book: Ulcer Disease: Investigation And Basis For Therapy. Eds. Szabo S, Swabb E, Marcel Dekker, New York, PP 459-485, 1991
Esam Z. Dajani (ed.), Gabriele Bianchi Porro (ed.)
Esam Z. Dajani, PhD, FACG